OPK

Company Overview — What Does OPKO HEALTH, INC. Do?

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida. OPKO HEALTH, INC. (OPK) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Phillip Frost and employs approximately 4,200 people, headquartered in MIAMI, Florida. With a market capitalization of $858M, OPK is one of the notable companies in the Healthcare sector.

OPKO HEALTH, INC. (OPK) Stock Rating — Reduce (April 2026)

As of April 2026, OPKO HEALTH, INC. receives a Reduce rating with a composite score of 35.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.OPK ranks #3,094 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, OPKO HEALTH, INC. ranks #451 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

OPK Stock Price and 52-Week Range

OPKO HEALTH, INC. (OPK) currently trades at $1.15. The stock lost $0.02 (2.1%) in the most recent trading session. The 52-week high for OPK is $1.85, which means the stock is currently trading -38.3% from its annual peak. The 52-week low is $1.11, putting the stock 3.2% above its annual trough. Recent trading volume was 840K shares, suggesting relatively thin trading activity.

Is OPK Overvalued or Undervalued? — Valuation Analysis

OPKO HEALTH, INC. (OPK) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 38.67x, compared to the Healthcare sector average of 23.63x — a premium of 64%. The price-to-book ratio stands at 0.70x, versus the sector average of 2.75x. The price-to-sales ratio is 1.41x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, OPK trades at 6.37x EV/EBITDA, versus 6.34x for the sector.

At current multiples, OPKO HEALTH, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

OPKO HEALTH, INC. Profitability — ROE, Margins, and Quality Score

OPKO HEALTH, INC. (OPK) earns a quality factor score of 35/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -13.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -8.8% versus the sector average of -33.1%.

On a margin basis, OPKO HEALTH, INC. reports gross margins of 30.9%, compared to 71.5% for the sector. The operating margin is -10.8% (sector: -66.1%). Net profit margin stands at -27.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -16.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

OPK Debt, Balance Sheet, and Financial Health

OPKO HEALTH, INC. has a debt-to-equity ratio of 27.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.97x, indicating strong short-term liquidity. Total debt on the balance sheet is $344M. Cash and equivalents stand at $415M.

OPK has a beta of 0.83, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for OPKO HEALTH, INC. is 63/100, reflecting average volatility within the normal range for its sector.

OPKO HEALTH, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, OPKO HEALTH, INC. reported revenue of $632M and earnings per share (EPS) of $-0.30. Net income for the quarter was $-170M. Gross margin was 30.9%. Operating income came in at $-65M.

In FY 2025, OPKO HEALTH, INC. reported revenue of $607M and earnings per share (EPS) of $-0.30. Net income for the quarter was $-226M. Gross margin was 33.9%. Revenue grew -14.9% year-over-year compared to FY 2024. Operating income came in at $-117M.

In Q3 2025, OPKO HEALTH, INC. reported revenue of $152M and earnings per share (EPS) of $0.03. Net income for the quarter was $22M. Gross margin was 32.9%. Revenue grew -12.6% year-over-year compared to Q3 2024. Operating income came in at $48M.

In Q2 2025, OPKO HEALTH, INC. reported revenue of $157M and earnings per share (EPS) of $-0.19. Net income for the quarter was $-148M. Gross margin was 31.5%. Revenue grew -13.9% year-over-year compared to Q2 2024. Operating income came in at $-60M.

Over the past 8 quarters, OPKO HEALTH, INC. has demonstrated a growth trajectory, with revenue expanding from $182M to $632M. Investors analyzing OPK stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

OPK Dividend Yield and Income Analysis

OPKO HEALTH, INC. (OPK) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

OPK Momentum and Technical Analysis Profile

OPKO HEALTH, INC. (OPK) has a momentum factor score of 24/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 37/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 63/100 reflects moderate short selling activity.

OPK vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, OPKO HEALTH, INC. (OPK) ranks #451 out of 838 stocks based on the Blank Capital composite score. This places OPK in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing OPK against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full OPK vs S&P 500 (SPY) comparison to assess how OPKO HEALTH, INC. stacks up against the broader market across all factor dimensions.

OPK Next Earnings Date

No upcoming earnings date has been announced for OPKO HEALTH, INC. (OPK) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy OPK? — Investment Thesis Summary

The quantitative profile for OPKO HEALTH, INC. suggests caution. The quality score of 35/100 flags below-average profitability. The value score of 23/100 indicates premium valuation. Momentum is weak at 24/100, a headwind for near-term performance. Low volatility (stability score 63/100) reduces downside risk.

In summary, OPKO HEALTH, INC. (OPK) earns a Reduce rating with a composite score of 35.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on OPK stock.

Related Resources for OPK Investors

Explore more research and tools: OPK vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare OPK head-to-head with peers: OPK vs AZN, OPK vs SLGL, OPK vs VMD.